Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ:SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric patients nine years of age and older.
  • Twyneo uses Sol-Gel's patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to release each of the active drug ingredients slowly.
  • The product is patent-protected until 2038.
  • Sol-Gel has partnered with Galderma to commercialize Twyneo in the U.S.
  • Sol-Gel expects to receive a regulatory milestone payment in conjunction with the approval.
  • Price Action: SLGL shares are up 2.56% at $12.42 during the market session on the last check Tuesday.
  • Related content: Benzinga's Full FDA Calendar.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareFDAGeneralAcne VulgarisBriefs